Latest News

Q4 2023 Watch: Bipartisan PEPFAR reauthorization push; ADAP coverage and Medicaid updates tracked.

HCV vaccine development requires addressing immune variability, access barriers, and community trust.

Research proves alcohol doesn't reduce DAA efficacy for HCV, yet payers continue restricting treatment.

Q3 2023 Watch: HIV disparities coverage; debt ceiling crisis impacts; Medicaid disenrollment trends tracked.

CDC report: HCV persists despite decade-old cure due to payer barriers and screening failures.

Q2 2023 Watch: Braidwood decision impacts PrEP coverage; ADAP coverage analysis and Medicaid program updates.

Biden FY2024 budget includes $9.7B PrEP program and $11B Hepatitis Elimination Program.

HCV Medicaid Access dashboard 2023 update: progress in eliminating treatment restrictions by state.

Q1 2023 Watch: Tennessee rejecting federal HIV funding; updates on ADAPs, Medicaid, veterans care, and harm reduction.

2023 outlook: CVS PBM discrimination lawsuit, Medicaid enforcement, and state-sponsored discrimination threats.

Q4 2022 Watch: HHS renewed opioid emergency; CANN launched monkeypox project; HEPLISAV-B hepatitis B vaccine covered.

Louisiana and Washington HCV subscription models save millions but fail elimination goals; cost alone isn't the barrier.

Monitoring report documents HCV treatment access challenges across ADAP, Medicaid, and VA systems.

Only 35% of privately insured and 23% of Medicaid patients initiate HCV treatment due to payer barriers.

Q3 2022 review of HCV drug access across ADAPs, Medicaid, and comprehensive harm reduction programs.

Community-based low-barrier HCV treatment for PWID significantly improves liver health outcomes.

Pediatric hepatitis investigations lack typical viruses but show adenovirus and potential COVID-19 involvement.

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

STI and HCV rates rise despite reduced screening, reflecting chronic public health underfunding.

Medicaid sobriety restrictions on HCV treatment contradict harm reduction and elimination goals.